Capricor Therapeutics (CAPR) Projected to Post Earnings on Tuesday

Key Points

• Q1 2026 results scheduled after the close on Tuesday, May 12, 2026 (conference call 4:30 PM ET); analysts expect EPS of ($0.55) and revenue of $40.0M, following a prior quarter where the company missed estimates (EPS ($0.62) vs. ($0.51) consensus).
• Significant insider selling: Director Karimah Es Sabar sold 61,265 shares and CFO Anthony Bergmann sold 25,000 shares on March 31, and insiders have sold 172,529 shares (~$5.30M) in the last 90 days while still owning 9.20% of the stock.
• Market and analyst backdrop: Shares traded at $32.56 (down 2.8%) with a $1.88B market cap and a 52‑week range of $4.30–$40.37; the consensus from nine Buys and one Sell is a "Moderate Buy" with an average price target of $46.09.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) is expected to release its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect Capricor Therapeutics to post earnings of ($0.55) per share and revenue of $40.00 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). On average, analysts expect Capricor Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Capricor Therapeutics Stock Down 2.8%

Shares of CAPR traded down $0.94 during mid-day trading on Tuesday, hitting $32.56. The stock had a trading volume of 222,249 shares, compared to its average volume of 1,261,348. The company has a market cap of $1.88 billion, a PE ratio of -14.44 and a beta of 0.48. The company's fifty day simple moving average is $31.11 and its two-hundred day simple moving average is $22.76. Capricor Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $40.37.

Insider Buying and Selling

In related news, Director Karimah Es Sabar sold 61,265 shares of the business's stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Anthony Bergmann sold 25,000 shares of the business's stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total value of $753,250.00. Following the transaction, the chief financial officer owned 8,223 shares of the company's stock, valued at $247,758.99. This trade represents a 75.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 172,529 shares of company stock valued at $5,302,440 in the last 90 days. Insiders own 9.20% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CAPR. Goldman Sachs Group Inc. boosted its position in Capricor Therapeutics by 39.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company's stock worth $3,902,000 after acquiring an additional 116,373 shares during the period. Legal & General Group Plc boosted its position in Capricor Therapeutics by 8.4% during the 2nd quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company's stock worth $410,000 after acquiring an additional 3,205 shares during the period. Rhumbline Advisers boosted its position in Capricor Therapeutics by 7.3% during the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company's stock worth $531,000 after acquiring an additional 3,636 shares during the period. Marshall Wace LLP acquired a new position in Capricor Therapeutics during the 2nd quarter worth $796,000. Finally, Jump Financial LLC boosted its position in Capricor Therapeutics by 42.6% during the 2nd quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company's stock worth $2,309,000 after acquiring an additional 69,515 shares during the period. Institutional investors and hedge funds own 21.68% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CAPR. Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the stock an "overweight" rating in a research report on Friday, March 13th. Piper Sandler restated an "overweight" rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, January 11th. B. Riley Financial boosted their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the company a "buy" rating in a research report on Friday, March 13th. Finally, HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, March 10th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Capricor Therapeutics has an average rating of "Moderate Buy" and an average price target of $46.09.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.